BCRX BioCryst Pharmaceuticals, Inc. - Common Stock

NASDAQ · Biotechnology · Ver en SEC EDGAR ↗
$9,88
Precio · Ago 18, 2026
Fundamentales a fecha de Ago 5, 2026
Rango 52S
$6–$11
74% of range
Calificación del Analista
BUY
17 analysts
Precio Objetivo
$21
+111% upside
P/E (TTM)
9.7
ROE
-97.6%
Margen de Beneficio Neto
30.2%

Acerca de BioCryst Pharmaceuticals, Inc. - Common Stock Descripción general de la empresa de Wikipedia

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.

Leer más

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.

History

The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.

In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.

Pipeline

BioCryst’s core development programs include:

Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).

FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.

Berotralstat has a PDUFA date for FDA approval on December 3, 2020.

On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.

BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.

FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).

Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.

Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.

In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.

BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.

In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.

In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.

In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.

Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗

Wikidata ↗

BCRX Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas

Precio
$9.88
Capitalización Bursátil
$2.51B
P/E (TTM)
9.7
BPA (TTM)
$1.21
Ingresos (TTM)
$875M
Rendimiento div.
—
ROE
-97.6%
Deuda/Capital
0.0
Rango 52S
$6 – $11

BCRX Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista

Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA

Ingresos y Beneficio Neto $875M
10-point trend, +3219.7%
2016-12-31 → 2025-12-31
BPA $1.21
6-point trend, +211.0%
2020-12-31 → 2025-12-31
Flujo de caja libre $345M
9-point trend, +687.4%
2016-12-31 → 2025-12-31
Márgenes 30.2%

Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?

Métrica
Tendencia a 5 años
BCRX
Mediana de Pares
P/E (TTM)
5-point trend, +147.9%
9.7
97.6
P/S (TTM) (P/V (TTM))
5-point trend, -88.3%
2.9
7.7
P/B (P/C)
5-point trend, +41.6%
-21.1
8.0
EV / EBITDA
5-point trend, +132.8%
6.5
—
Price / FCF (Precio / FCF)
5-point trend, +127.3%
7.3
—

Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC

Métrica
Tendencia a 5 años
BCRX
Mediana de Pares
Operating Margin (Margen Operativo)
5-point trend, +134.5%
39.0%
—
Net Profit Margin (Margen de Beneficio Neto)
5-point trend, +125.8%
30.2%
-51.7%
ROA
5-point trend, +231.7%
52.5%
-44.2%
ROE
5-point trend, -167.3%
-97.6%
-63.5%
ROIC
5-point trend, +54.3%
-282.4%
—

Salud financiera Deuda, liquidez, solvencia — solidez del balance general

Métrica
Tendencia a 5 años
BCRX
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
5-point trend, +100.0%
0.0
18.7
Current Ratio (Ratio corriente)
5-point trend, -62.2%
2.1
4.9
Quick Ratio (Ratio Rápido)
5-point trend, -62.2%
1.9
—

Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años

Métrica
Tendencia a 5 años
BCRX
Mediana de Pares
Revenue YoY (Ingresos interanuales)
5-point trend, +456.6%
94.1%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
5-point trend, +456.6%
47.8%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
5-point trend, +456.6%
117.9%
—

Métricas por acción BPA, valor contable por acción, flujo de caja por acción, dividendo por acción

Métrica
Tendencia a 5 años
BCRX
Mediana de Pares
EPS (Diluted) (BPA (Diluido))
5-point trend, +217.5%
$1.21
—

Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar

Métrica
Tendencia a 5 años
BCRX
Mediana de Pares

BCRX Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista

COMPRA 17 analistas
  • Compra fuerte 5 29,4%
  • Compra 10 58,8%
  • Mantener 2 11,8%
  • Venta 0 0,0%
  • Venta fuerte 0 0,0%

Precio objetivo a 12 meses

11 analistas · 2026-08-17
Objetivo mediano $17.00 +72,1%
Objetivo medio $20.82 +110,7%

Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados

Sorpresa Media
0.02%
Período EPS Actual EPS est. Sorpresa
30 de junio de 2026 $0.30 $0.12 0.18%
31 de marzo de 2026 $-0.09 $0.05 -0.14%
31 de diciembre de 2025 $0.01 $0.04 -0.03%
30 de septiembre de 2025 $0.06 $0.04 0.02%
30 de junio de 2025 $0.04 $0.01 0.03%
31 de marzo de 2025 $0.00 $-0.07 0.07%

Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector

Ticker Capitalización Bursátil P/E Ingresos interanuales Margen Neto ROE Margen Bruto
BCRX $1.66B 6.4 94.1% 30.2% -97.6% —
BEAM $2.82B -34.2 120.0% -57.2% -7.0% —
KOD $1.73B -6.5 — — -202.0% —
SLS $577M -15.1 — — -55.4% —
RARE $2.22B -3.9 20.2% -85.4% -1613.2% —
COAG — — — — — —
KLRA — — — — — —
CDNA $959M -47.1 13.8% -5.6% -6.8% —
PGEN $1.48B -3.1 146.7% -2588.2% 3159.1% —
VERA — -10.9 — — -55.9% —
MLYS $2.96B -15.8 — — -32.2% —

Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja

Estado de resultados 16
Datos anuales de Estado de resultados para BCRX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +6328.8% $875M $451M $331M $271M $157M $18M $49M $21M $25M $26M $48M $14M
Cost of Revenue 11-point trend, +1907400.0% $19M $12M $4M $6M $7M $2M $4M · $1M $2M $1M $1.0K
R&D Expense 12-point trend, +220.7% $166M $175M $217M $253M $209M $123M $107M $85M $67M $61M $73M $52M
SG&A Expense 12-point trend, +4572.9% $349M $266M $214M $159M $119M $68M $37M $30M $14M $11M $13M $7M
Operating Expenses 12-point trend, +799.1% $534M $453M $435M $419M $335M $193M $148M $115M $83M $75M $88M $59M
Operating Income 12-point trend, +845.0% $341M $-3M $-104M $-148M $-178M $-175M $-99M $-94M $-57M $-49M $-39M $-46M
Interest Expense 10-point trend, +2065.6% · · $108M $99M $59M $15M $12M $9M $9M $6M $5M $5M
Other Non-op 4-point trend, +23.3% $-74M $-84M $-123M $-96M · · · · · · · ·
Pretax Income 7-point trend, +345.5% $267M $-87M $-226M $-244M $-182M $-183M $-109M · · · · ·
Income Tax 11-point trend, +3530000.00 $4M $2M $310.0K $3M $2M $0 $0 $0 $0 $0 $0 ·
Net Income 12-point trend, +683.9% $264M $-89M $-227M $-247M $-184M $-183M $-109M $-101M $-66M $-55M $-43M $-45M
EPS (Basic) 6-point trend, +215.6% $1.26 $-0.43 $-1.18 $-1.33 $-1.03 $-1.09 · · · · · ·
EPS (Diluted) 6-point trend, +211.0% $1.21 $-0.43 $-1.18 $-1.33 $-1.03 $-1.09 · · · · · ·
Shares (Basic) 6-point trend, +25.5% 209,893,000 206,696,000 192,198,000 185,908,000 179,117,000 167,267,000 · · · · · ·
Shares (Diluted) 12-point trend, +227.3% 218,581,000 206,696,000 192,198,000 185,908,000 179,117,000 167,267,000 115,600,000 103,185,000 84,451,000 73,699,000 72,901,000 66,773,000
EBITDA 11-point trend, +850.9% $342M $-1M $-102M $-147M $-177M $-174M $-99M $-93M · $-48M $-39M $-46M
Balance general 27
Datos anuales de Balance general para BCRX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +64.5% $90M $105M $111M $305M $504M $272M $114M $27M $50M $22M $29M $55M
Short-term Investments 2-point trend, -14.4% $185M $216M · · · · · · · · · ·
Receivables 12-point trend, +2675.2% $107M $79M $57M $51M $29M $9M $22M $4M $6M $9M $6M $4M
Inventory 11-point trend, +690.3% $5M $8M $29M $28M $16M $7M $0 $2M · $500.0K $2M $683.0K
Prepaid Expense 12-point trend, +178.4% $17M $14M $20M $13M $10M $6M $4M $2M $1M $1M $3M $6M
Current Assets 12-point trend, +352.6% $404M $422M $496M $516M $566M $324M $164M $114M $125M $67M $64M $89M
PP&E (Net) 12-point trend, +4143.0% $9M $8M $8M $9M $9M $7M $7M $9M $10M $10M $5M $207.0K
PP&E (Gross) 12-point trend, +27.7% $18M $20M $19M $18M $17M $14M $14M $15M $15M $15M $19M $14M
Accum. Depreciation 12-point trend, -33.0% $9M $12M $11M $10M $8M $7M $7M $6M $5M $5M $14M $14M
Other Non-current Assets 12-point trend, -6.0% $6M $5M $80.0K $7M $6M $4M $4M $978.0K $2M $4M $5M $6M
Total Assets 12-point trend, +275.6% $514M $490M $517M $550M $588M $335M $175M $147M $178M $90M $122M $137M
Accounts Payable 12-point trend, +455.5% $16M $12M $21M $14M $28M $19M $14M $8M $6M $4M $9M $3M
Accrued Liabilities 12-point trend, +1015.8% $126M $113M $103M $88M $73M $34M $21M $16M $13M $11M $16M $11M
Short-term Debt 7-point trend, +0.0% · · · · · $30M $30M $29M $29M $28M $28M $30M
Current Liabilities 12-point trend, +242.2% $196M $160M $150M $106M $104M $106M $92M $69M $75M $54M $62M $57M
Capital Leases 6-point trend, +121.4% $9M $8M $8M $4M $6M $4M · · · · · ·
Other Non-current Liabilities · · · · · · · $3M · · · ·
Total Liabilities 3-point trend, -34.9% $633M $966M $972M · · · · · · · · ·
Long-term Debt 6-point trend, +1196.3% · · · · $298M $123M $50M $30M $23M $23M · ·
Total Debt 11-point trend, -100.0% $0 $315M $303M $232M $136M $150M $30M $29M · $28M $30M $30M
Common Stock 12-point trend, +196.0% $2M $2M $2M $2M $2M $2M $2M $1M $984.0K $738.0K $734.0K $720.0K
Paid-in Capital 12-point trend, +155.1% $1.38B $1.29B $1.22B $1.16B $1.10B $1.00B $877M $780M $715M $567M $558M $543M
Retained Earnings 12-point trend, -221.9% $-1.51B $-1.77B $-1.68B $-1.45B $-1.21B $-1.02B $-841M $-732M $-632M $-566M $-511M $-468M
AOCI 12-point trend, +129.2% $38.0K $921.0K $1M $26.0K $177.0K $3.0K $39.0K $-297.0K $-243.0K $-12.0K $-206.0K $-130.0K
Stockholders' Equity 12-point trend, -257.5% $-119M $-476M $-456M $-295M $-107M $-19M $38M $49M $84M $2M $48M $76M
Liabilities + Equity 12-point trend, +275.6% $514M $490M $517M $550M $588M $335M $175M $147M $178M $90M $122M $137M
Shares Outstanding 12-point trend, +196.1% 213,060,000 208,543,000 205,771,000 187,906,000 184,350,000 176,883,000 154,082,000 110,063,000 98,411,000 73,782,000 73,355,000 71,955,000
Flujo de Efectivo 16
Datos anuales de Flujo de Efectivo para BCRX
Métrica Tendencia 202520242023202220212020201920182017201620152014
D&A 12-point trend, +684.7% $1M $1M $2M $1M $777.0K $748.0K $724.0K $770.0K $704.0K $483.0K $180.0K $177.0K
Stock-based Comp 12-point trend, +735.9% $85M $65M $56M $45M $35M $15M $18M $9M $13M $8M $10M $10M
Deferred Tax 5-point trend, -662.3% $-1M $-354.0K $-682.0K $11.0K $-159.0K · · · · · · ·
Other Non-cash 11-point trend, +53.3% $-2M $-29M $75M $39M $6M $30M $870.0K $-1M · $-7M $20M $-4M
Operating Cash Flow 12-point trend, +1001.1% $347M $-52M $-95M $-162M $-142M $-135M $-90M $-93M $-41M $-53M $-13M $-39M
CapEx 12-point trend, +2228.3% $2M $1M $2M $1M $2M $514.0K $343.0K $366.0K $328.0K $5M $5M $106.0K
Investing Cash Flow 11-point trend, +23.9% $-14M $53M $-131M $-128M $16M $-7M $78M $5M $-65M $23M $-18M ·
Debt Issued 5-point trend, +0.00 $0 $0 $300M $73M $0 · · · · · · ·
Net Debt Issued 3-point trend, -200.0% $-300M $0 $300M · · · · · · · · ·
Stock Issued 8-point trend, -100.0% · · $0 $0 $50M $93M $58M $53M $134M · · $107M
Net Stock Activity 7-point trend, -100.0% · · $0 $0 $50M $93M $58M $53M · · · $107M
Financing Cash Flow 11-point trend, -6486.8% $-350M $-6M $32M $88M $360M $301M $99M $63M $136M $23M $5M ·
Net Change in Cash 12-point trend, -144.9% $-15M $-6M $-194M $-201M $233M $159M $87M $-25M $30M $-7M $-26M $33M
Taxes Paid 3-point trend, +95.5% $3M $2M $1M · · · · · · · · ·
Free Cash Flow 11-point trend, +992.2% $345M $-53M $-97M $-163M $-145M $-138M $-90M $-93M · $-59M $-18M $-39M
Levered FCF 4-point trend, -35.1% · · $-206M $-263M $-205M $-152M · · · · · ·
Rentabilidad 7
Datos anuales de Rentabilidad para BCRX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Operating Margin 11-point trend, +111.6% 39.0% -0.56% -31.3% -54.8% -113.1% -981.1% -203.7% -456.2% · -184.4% -81.7% -336.4%
Net Margin 11-point trend, +109.1% 30.2% -19.7% -68.4% -91.2% -117.1% -1026.4% -223.0% -490.2% · -209.2% -89.1% -332.1%
Pretax Margin 6-point trend, +103.0% 30.6% -19.3% -68.3% -90.2% -115.7% -1026.4% · · · · · ·
EBITDA Margin 11-point trend, +111.7% 39.1% -0.29% -30.8% -54.3% -112.6% -976.9% -202.2% -452.5% · -182.6% -81.4% -335.0%
ROA 11-point trend, +208.0% 52.5% -17.6% -42.5% -43.4% -39.9% -71.7% -67.6% -62.3% · -52.0% -32.9% -48.7%
ROE 11-point trend, +19.5% -97.6% 18.8% 52.3% 92.0% 144.9% -2543.5% 7257.4% -165.8% · -223.7% -69.8% -121.3%
ROIC 6-point trend, -110.8% -282.4% 1.6% 68.2% 238.4% -618.4% -133.9% · · · · · ·
Liquidez y Solvencia 5
Datos anuales de Liquidez y Solvencia para BCRX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Current Ratio 11-point trend, +33.2% 2.1 2.6 3.3 4.9 5.5 3.1 1.8 1.6 · 1.2 1.0 1.5
Quick Ratio 11-point trend, +105.8% 1.9 1.1 1.1 3.4 5.1 2.7 1.5 0.4 · 0.6 0.5 0.9
Debt / Equity 11-point trend, -100.0% 0.0 -0.7 -0.7 -0.8 -1.3 -7.8 0.8 0.6 · 17.9 0.6 0.4
LT Debt / Equity 6-point trend, +100.0% 0.0 -0.7 -0.7 -0.8 -1.3 -6.2 · · · · · ·
Interest Coverage 9-point trend, +89.5% · · -1.0 -1.5 -3.0 -12.1 -8.4 -10.3 · -7.5 -7.6 -9.2
Eficiencia 3
Datos anuales de Eficiencia para BCRX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Asset Turnover 11-point trend, +1088.9% 1.7 0.9 0.6 0.5 0.3 0.1 0.3 0.1 · 0.2 0.4 0.1
Inventory Turnover 9-point trend, +97455.2% 2.8 0.4 0.2 0.3 0.6 0.4 · · · 2.2 1.2 0.0
Receivables Turnover 10-point trend, -1.6% 9.4 6.6 6.2 6.8 8.3 1.2 3.7 4.0 · 3.5 9.6 ·
Por Acción 5
Datos anuales de Por Acción para BCRX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Book Value / Share 11-point trend, -153.2% $-0.56 $-2.28 $-2.21 $-1.57 $-0.58 $-0.11 $0.25 $0.45 · $0.02 $0.65 $1.05
Revenue / Share 10-point trend, +504.6% $4.00 $2.18 $1.72 $1.46 $0.88 $0.11 $0.42 $0.20 · $0.36 $0.66 ·
Cash Flow / Share 10-point trend, +983.4% $1.59 $-0.25 $-0.49 $-0.87 $-0.79 $-0.82 $-0.77 $-0.90 · $-0.73 $-0.18 ·
Cash / Share 11-point trend, -44.4% $0.42 $0.50 $0.54 $1.62 $2.74 $1.54 $0.74 $0.24 · $0.30 $0.39 $0.76
EPS (TTM) 11-point trend, +301.7% $1.21 $-0.43 $-1.18 $-1.33 $-1.03 $-1.09 $-0.61 $-0.61 $-0.61 $-0.61 $-0.60 ·
Tasas de Crecimiento 3
Datos anuales de Tasas de Crecimiento para BCRX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -88.0% 94.1% 36.0% 22.4% 72.3% 782.4% · · · · · · ·
Revenue CAGR 3Y 3-point trend, -71.0% 47.8% 42.1% 165.0% · · · · · · · · ·
Revenue CAGR 5Y 117.9% · · · · · · · · · · ·
Valoración (TTM) 13
Datos anuales de Valoración (TTM) para BCRX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +6328.8% $875M $451M $331M $271M $157M $18M $49M $21M $25M $26M $48M $14M
Net Income TTM 12-point trend, +683.9% $264M $-89M $-227M $-247M $-184M $-183M $-109M $-101M $-66M $-55M $-43M $-45M
Market Cap 11-point trend, +89.9% $1.66B $1.57B $1.23B $2.16B $2.55B $1.32B $532M $888M · $467M $757M $875M
Enterprise Value 11-point trend, +63.1% $1.39B $1.78B $1.43B $2.08B $2.18B $1.20B $447M $891M · $473M $758M $850M
P/E 11-point trend, +137.5% 6.4 -17.5 -5.1 -8.6 -13.4 -6.8 -5.7 -13.2 -8.0 -10.4 -17.2 ·
P/S 11-point trend, -97.0% 1.9 3.5 3.7 8.0 16.2 74.0 10.9 43.0 · 17.7 15.7 64.3
P/B 11-point trend, -220.6% -13.9 -3.3 -2.7 -7.3 -23.9 -68.4 13.9 18.0 · 296.0 15.9 11.6
P / Cash Flow 11-point trend, +121.1% 4.8 -30.1 -13.0 -13.3 -18.0 -9.6 -5.9 -9.6 · -8.7 -57.7 -22.7
P / FCF 11-point trend, +121.3% 4.8 -29.5 -12.7 -13.2 -17.7 -9.6 -5.9 -9.6 · -8.0 -41.5 -22.6
EV / EBITDA 11-point trend, +121.7% 4.1 -1371.2 -14.0 -14.2 -12.3 -6.9 -4.5 -9.5 · -9.8 -19.3 -18.7
EV / FCF 11-point trend, +118.3% 4.0 -33.5 -14.6 -12.8 -15.1 -8.7 -5.0 -9.6 · -8.1 -41.6 -22.0
EV / Revenue 11-point trend, -97.5% 1.6 3.9 4.3 7.7 13.9 67.1 9.2 43.1 · 18.0 15.7 62.5
Earnings Yield 11-point trend, +367.0% 15.5% -5.7% -19.7% -11.6% -7.4% -14.6% -17.7% -7.6% -12.4% -9.6% -5.8% ·

Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años

Estado de resultados
2025-12-312024-12-312023-12-312022-12-312021-12-31
Ingresos $875M$451M$331M$271M$157M
Margen Operativo % 39.0%-0.56%-31.3%-54.8%-113.1%
Beneficio neto $264M$-89M$-227M$-247M$-184M
EPS Diluido $1.21$-0.43$-1.18$-1.33$-1.03
Balance general
2025-12-312024-12-312023-12-312022-12-312021-12-31
Deuda / Patrimonio 0.0-0.7-0.7-0.8-1.3
Ratio corriente 2.12.63.34.95.5
Ratio Rápido 1.91.11.13.45.1
Flujo de Efectivo
2025-12-312024-12-312023-12-312022-12-312021-12-31
Flujo de caja libre $345M$-53M$-97M$-163M$-145M

Últimas noticias Noticias recientes que mencionan a esta empresa

Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos

📊

Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.

Tu selección se guarda y te sigue en todos los tickers.

Propietarios institucionales (13F) 346 declarantes · $2.1B total · A fecha de 30 de junio de 2026

Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.

Actividad institucional — Q2 2026 vs trimestre anterior
Nuevas posiciones Posiciones cerradas Aumentado Disminuido Cambio neto de acciones
63 (-7 vs trimestre anterior) 34 (-7 vs trimestre anterior) 130 (+19 vs trimestre anterior) 83 (+3 vs trimestre anterior) +25.9M

Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.

Institución Valor Acciones % de 13F rastreadas Tipo
RA CAPITAL MANAGEMENT, L.P. $158 271 860 15 827 186 7,51% Acciones
STATE STREET CORP $151 910 980 15 191 098 7,21% Acciones
DEERFIELD MANAGEMENT COMPANY, L.P. $150 964 030 15 096 403 7,16% Acciones
VANGUARD CAPITAL MANAGEMENT LLC $113 642 360 11 364 236 5,39% Acciones
VANGUARD PORTFOLIO MANAGEMENT LLC $111 391 580 11 139 158 5,29% Acciones
TCG Crossover Management, LLC $110 209 680 11 020 968 5,23% Acciones
PERCEPTIVE ADVISORS LLC $103 088 880 10 308 888 4,89% Acciones
JANUS HENDERSON GROUP PLC $83 961 589 8 814 865 3,98% Acciones
Vestal Point Capital, LP $83 000 000 8 300 000 3,94% Acciones
TWO SIGMA INVESTMENTS, LP $67 753 490 6 775 349 3,21% Acciones
GEODE CAPITAL MANAGEMENT, LLC $53 581 572 5 356 880 2,54% Acciones
Aberdeen Group plc $53 108 710 5 310 871 2,52% Acciones
Frazier Life Sciences Management, L.P. $40 092 400 4 009 240 1,90% Acciones
GOLDMAN SACHS GROUP INC $35 393 210 3 539 321 1,68% Acciones
MILLENNIUM MANAGEMENT LLC $33 947 290 3 394 729 1,61% Acciones
TWO SIGMA ADVISERS, LP $31 895 074 4 089 112 1,51% Acciones
RP Management, LLC $28 846 155 3 846 154 1,37% Acciones
DIMENSIONAL FUND ADVISORS LP $27 161 110 2 716 111 1,29% Acciones
Fisher Asset Management, LLC $26 040 270 2 604 027 1,24% Acciones
RENAISSANCE TECHNOLOGIES LLC $25 302 900 2 530 290 1,20% Acciones
Kynam Capital Management, LP $25 226 600 2 522 660 1,20% Acciones
Candriam S.C.A. $25 125 293 2 514 949 1,19% Acciones
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $23 532 910 2 353 291 1,12% Acciones
RICE HALL JAMES & ASSOCIATES, LLC $23 320 430 2 332 043 1,11% Acciones
AQR CAPITAL MANAGEMENT LLC $21 850 110 2 185 011 1,04% Acciones
Nantahala Capital Management, LLC $19 011 600 1 901 160 0,90% Acciones
Eversept Partners, LP $18 656 530 1 865 653 0,89% Acciones
ORBIMED ADVISORS LLC $18 520 000 1 852 000 0,88% Acciones
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND $18 449 120 1 844 912 0,88% Acciones
VANGUARD FIDUCIARY TRUST CO $17 595 730 1 759 573 0,83% Acciones
CITADEL ADVISORS LLC $17 591 600 1 759 160 0,83% Acciones
IMC-Chicago, LLC $16 343 360 1 634 336 0,78% Acciones
Parkman Healthcare Partners LLC $16 242 790 1 624 279 0,77% Acciones
JANE STREET GROUP, LLC $14 267 680 1 426 768 0,68% Acciones
OP Asset Management Ltd $13 409 900 1 340 990 0,64% Acciones
SUSQUEHANNA INTERNATIONAL GROUP, LLP $11 956 510 1 195 651 0,57% Acciones
Pictet Asset Management Holding SA $11 951 392 1 249 771 0,57% Acciones
BNP PARIBAS FINANCIAL MARKETS $11 740 520 1 174 052 0,56% Acciones
FIRST TRUST ADVISORS LP $11 204 690 1 120 469 0,53% Acciones
JANE STREET GROUP, LLC $9 944 130 994 413 0,47% Opción de compra
Cubist Systematic Strategies, LLC $9 462 419 1 246 696 0,45% Acciones
MOORE CAPITAL MANAGEMENT, LP $8 483 360 848 336 0,40% Acciones
FMR LLC $8 062 330 806 233 0,38% Acciones
BANK OF AMERICA CORP /DE/ $7 754 020 775 402 0,37% Acciones
ExodusPoint Capital Management, LP $7 449 170 744 917 0,35% Acciones
Man Group plc $7 324 800 732 480 0,35% Acciones
Rosalind Advisors, Inc. $7 215 040 721 504 0,34% Acciones
Schonfeld Strategic Advisors LLC $7 108 160 710 816 0,34% Acciones
BlackRock, Inc. $5 984 400 598 440 0,28% Acciones
Elmind Capital, LP $5 200 000 520 000 0,25% Acciones
Bridgewater Associates, LP $4 910 570 491 057 0,23% Acciones
NAN FUNG TRINITY (HK) LTD $4 500 000 450 000 0,21% Acciones
SPHERA FUNDS MANAGEMENT LTD. $4 220 510 422 051 0,20% Acciones
Swiss National Bank $4 152 680 415 268 0,20% Acciones
Susquehanna Portfolio Strategies, LLC $4 047 040 404 704 0,19% Acciones
DAFNA Capital Management LLC $4 002 480 400 248 0,19% Acciones
Hudson Bay Capital Management LP $4 000 000 400 000 0,19% Acciones
Aquatic Capital Management LLC $3 628 950 362 895 0,17% Acciones
DOLIVER CAPITAL ADVISORS, INC. $3 563 603 374 328 0,17% Acciones
Assenagon Asset Management S.A. $3 530 440 353 044 0,17% Acciones
Kodai Capital Management LP $3 515 993 468 799 0,17% Acciones
MACKENZIE FINANCIAL CORP $3 472 990 347 299 0,16% Acciones
CITIGROUP INC $3 467 520 346 752 0,16% Acciones
Phocas Financial Corp. $3 405 410 340 541 0,16% Acciones
SUSQUEHANNA INTERNATIONAL GROUP, LLP $3 238 000 323 800 0,15% Opción de compra
ALPS ADVISORS INC $3 179 600 317 960 0,15% Acciones
ALLIANCEBERNSTEIN L.P. $3 121 694 327 909 0,15% Acciones
RHUMBLINE ADVISERS $2 798 390 279 839 0,13% Acciones
Rafferty Asset Management, LLC $2 656 180 265 618 0,13% Acciones
Point72 Asset Management, L.P. $2 609 170 260 917 0,12% Acciones
Nuveen, LLC $2 599 030 259 903 0,12% Acciones
NFJ INVESTMENT GROUP, LLC $2 568 330 256 833 0,12% Acciones
Nebula Research & Development LLC $2 567 121 286 509 0,12% Acciones
WINTON GROUP Ltd $2 556 000 255 600 0,12% Acciones
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $2 459 444 258 345 0,12% Acciones
MARTINGALE ASSET MANAGEMENT L P $2 425 080 242 508 0,12% Acciones
WELLINGTON MANAGEMENT GROUP LLP $2 324 670 232 467 0,11% Acciones
CITADEL ADVISORS LLC $2 322 000 232 200 0,11% Opción de compra
IEQ CAPITAL, LLC $2 274 210 227 421 0,11% Acciones
Bank of New York Mellon Corp $2 251 670 225 167 0,11% Acciones
D. E. Shaw & Co., Inc. $2 249 120 224 912 0,11% Acciones
JUPITER ASSET MANAGEMENT LTD $2 221 030 222 103 0,11% Acciones
HUSSMAN STRATEGIC ADVISORS, INC. $2 100 000 210 000 0,10% Acciones
PFM Health Sciences, LP $2 073 570 207 357 0,10% Acciones
VANGUARD ASSET MANAGEMENT, Ltd $1 962 800 196 280 0,09% Acciones
TUDOR INVESTMENT CORP ET AL $1 951 280 195 128 0,09% Acciones
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1 853 000 185 300 0,09% Opción de venta
VIRGINIA RETIREMENT SYSTEMS ET Al $1 820 161 233 354 0,09% Acciones
Engineers Gate Manager LP $1 750 020 175 002 0,08% Acciones
Squarepoint Ops LLC $1 747 140 174 714 0,08% Acciones
QTR Family Wealth, LLC $1 610 820 161 082 0,08% Acciones
Gotham Asset Management, LLC $1 564 210 156 421 0,07% Acciones
CITADEL ADVISORS LLC $1 450 000 145 000 0,07% Opción de venta
Corient Private Wealth LP $1 429 860 142 986 0,07% Acciones
NEW YORK STATE COMMON RETIREMENT FUND $1 386 570 138 657 0,07% Acciones
Quantinno Capital Management LP $1 374 530 137 453 0,07% Acciones
MetLife Investment Management, LLC $1 356 700 135 670 0,06% Acciones
PROFUND ADVISORS LLC $1 340 340 134 034 0,06% Acciones
Virtus Investment Advisers, LLC $1 336 640 133 664 0,06% Acciones
ADAR1 Capital Management, LLC $1 330 000 133 000 0,06% Acciones

Informantes de la empresa 51 insiders · 21 directivos · 30 consejeros

Insider Rol Última actividad Acciones en propiedad Compras 12m Ventas 12m Neto 12m
Babar Ghias Chief Financial Officer 17 de diciembre de 2025 A 268 700 0 0 $0
Anthony Doyle Chief Financial Officer 19 de diciembre de 2024 A 377 867 0 0 $0
Thomas R Staab II Senior Vice President and CFO 21 de febrero de 2020 A 125 176 0 0 $0
Stuart Grant SR VP & CFO 16 de marzo de 2011 M 57 102 0 0 $0
Charles K Gayer President and CCO 22 de diciembre de 2025 M 952 583 0 0 $0
Claude J Bennett Chief Operating Officer 14 de marzo de 2008 A 65 730 0 0 $0
Alane P Barnes Chief Legal Officer 13 de mayo de 2026 M 400 703 0 7 $-3 461 969
Sandeep Menon Chief R&D Officer 6 de abril de 2026 A 205 150 0 0 $0
Helen M. Thackray Chief R&D Officer 31 de marzo de 2025 F 377 318 0 0 $0
Michael L Jones Exec. Director, Finance - PAO 19 de diciembre de 2022 A 16 653 0 0 $0
Yarlagadda S Babu Chief Discovery Officer 14 de noviembre de 2022 M 298 541 0 0 $0
William P Sheridan Chief Medical Officer 10 de marzo de 2022 M 37 954 0 0 $0
Megan Sniecinski Chief Business Officer 15 de diciembre de 2020 A 45 000 0 0 $0
Lynne Powell Senior VP - CCO 28 de enero de 2019 M 0 0 0 $0
David Mccullough VP 15 de marzo de 2012 F 24 124 0 0 $0
Robert S Lowrey Controller, PAO 7 de febrero de 2011 A 9 766 0 0 $0
Mike Mills Principal Accounting Officer 12 de marzo de 2010 M 0 0 0 $0
Michael A Darwin Principal Accounting Officer 31 de julio de 2008 P 3 048 0 0 $0
Jonathan M Nugent VP Corp Communications 31 de julio de 2007 P 508 0 0 $0
James W Alexander SR. VP, Chief Medical Officer 31 de julio de 2007 P 3 659 0 0 $0
Randall B Riggs Senior VP Business Development 16 de mayo de 2007 A 1 928 0 0 $0
Amy E Mckee Consejero 11 de junio de 2026 A 47 177 0 1 $-100 285
Theresa Heggie Consejero 11 de junio de 2026 A 80 646 0 1 $-504 823
Machelle Sanders Consejero 11 de junio de 2026 A 45 936 0 1 $-68 544
Jill C. Milne Consejero 11 de junio de 2026 A 31 938 0 0 $0
Steven Frank Consejero 11 de junio de 2026 A 35 459 0 0 $0
Steven K Galson Consejero 11 de junio de 2026 A 27 794 0 0 $0
Jon P Stonehouse Consejero 11 de junio de 2026 A 1 339 775 0 0 $0
Vincent Milano Consejero 11 de junio de 2026 A 108 483 0 0 $0
Alan G Levin Consejero 11 de junio de 2026 A 79 565 0 0 $0
Nancy J Hutson Consejero 12 de junio de 2025 A 99 138 0 0 $0
George B Abercrombie Consejero 12 de junio de 2024 A 36 431 0 0 $0
Steve Aselage Consejero 12 de junio de 2024 A 70 159 0 0 $0
Kenneth B Lee JR Consejero 13 de junio de 2023 A 68 863 0 0 $0
Robert Alexander Ingram Consejero 28 de febrero de 2023 A 100 198 0 0 $0
Stanley C Erck Consejero 28 de noviembre de 2018 M 48 333 0 0 $0
Fred Cohen Consejero 20 de junio de 2018 A 119 410 0 0 $0
Sanj K Patel Consejero 24 de mayo de 2017 A — 0 0 $0
Charles A Sanders Consejero 29 de febrero de 2016 A 12 971 0 0 $0
Peder Jensen Consejero 2 de mayo de 2014 A 60 000 0 0 $0
John L Higgins Consejero 23 de mayo de 2012 A — 0 0 $0
HOROVITZ ZOLA P Consejero 23 de mayo de 2012 A 3 000 0 0 $0
Stephen R Biggar Consejero 12 de mayo de 2011 A — 0 0 $0
Beth C Seidenberg Consejero 13 de mayo de 2010 A 3 000 0 0 $0
William W Featheringill Consejero 13 de mayo de 2010 A 231 538 0 0 $0
William M Spencer III Consejero 16 de mayo de 2007 A 186 761 0 0 $0
Joseph H Sherrill JR Consejero 16 de mayo de 2007 A 451 900 0 0 $0
Charles E Bugg Consejero 18 de marzo de 2007 A 62 439 0 0 $0
GORDON CARL L Consejero 17 de mayo de 2006 A 1 100 000 0 0 $0
John A Montgomery Consejero 4 de noviembre de 2003 M 46 785 0 0 $0

Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto

Activistas y propietarios del %+ 5 15 tenencias

Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.

Declarante Presentado Participación Estado Propósito Presentación
Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 presentaciones 31 de julio de 2018 — Presentación inicial — SEC
RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. 2 de abril de 2018 — Presentación inicial Inversión pasiva SEC
Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 presentaciones 16 de agosto de 2016 — Presentación inicial — SEC
Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 presentaciones 23 de octubre de 2012 — Presentación inicial — SEC
Julian C. Baker, Felix J. Baker ×4 presentaciones 13 de octubre de 2011 — Presentación inicial — SEC
L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 presentaciones 20 de agosto de 2007 — Presentación inicial — SEC
Persona informante no revelada, Persona informante no revelada, Persona informante no revelada 7 de diciembre de 2005 — Presentación inicial — SEC
Persona informante no revelada, Persona informante no revelada, Persona informante no revelada 7 de diciembre de 2005 — Presentación inicial — SEC
Persona informante no revelada, Persona informante no revelada, Persona informante no revelada 7 de diciembre de 2005 — Presentación inicial — SEC
Persona informante no revelada 13 de octubre de 2005 — Presentación inicial — SEC
Persona informante no revelada, Persona informante no revelada, Persona informante no revelada 26 de febrero de 2004 — Presentación inicial — SEC
Persona informante no revelada, Persona informante no revelada, Persona informante no revelada 25 de febrero de 2004 — Presentación inicial — SEC
Persona informante no revelada, Persona informante no revelada, Persona informante no revelada 24 de febrero de 2004 — Presentación inicial — SEC
Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 presentaciones 31 de octubre de 2003 — Presentación inicial — SEC
William W. Featheringill 14 de febrero de 2002 — Presentación inicial — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Propiedad de ETFs Mantenido por 53 ETFs

El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.

Fondo Ponderación Unidades A fecha de Fuente
PBE · Invesco Exchange-Traded Fund Trust 2,65% 1 023 838 SH 8 de agosto de 2026 Diario
BBP · ETFis Series Trust I 1,93% 125 015 NS 30 de abril de 2026 N-PORT
ABLS · Abacus FCF ETF Trust 1,26% 1 682 NS 30 de abril de 2026 N-PORT
LABU · Direxion Shares ETF Trust 0,67% 381 305 NS 30 de abril de 2026 N-PORT
FYC · First Trust Exchange-Traded AlphaDE… 0,54% 612 341 NS 30 de abril de 2026 N-PORT
CALF · Pacer Funds Trust 0,41% 1 556 494 NS 30 de abril de 2026 N-PORT
FYX · First Trust Exchange-Traded AlphaDE… 0,28% 364 624 NS 30 de abril de 2026 N-PORT
BFOR · ALPS ETF Trust 0,25% 59 894 NS 31 de mayo de 2026 N-PORT
OMFS · Invesco Exchange-Traded Self-Indexe… 0,24% 72 535 SH 8 de agosto de 2026 Diario
GSSC · Goldman Sachs ETF Trust 0,19% 213 133 NS 31 de mayo de 2026 N-PORT
SMLF · iShares Trust 0,17% 758 958 SH 8 de agosto de 2026 Diario
IBBQ · Invesco Exchange-Traded Fund Trust … 0,16% 13 830 SH 8 de agosto de 2026 Diario
IBB · iShares Trust 0,15% 1 580 105 SH 8 de agosto de 2026 Diario
ESSC · Strategy Shares 0,15% 4 183 NS 30 de abril de 2026 N-PORT
VTWG · VANGUARD SCOTTSDALE FUNDS 0,14% 249 665 SH 8 de agosto de 2026 Diario
IWO · iShares Trust 0,13% 2 097 061 SH 8 de agosto de 2026 Diario
BIB · ProShares Trust 0,11% 9 271 NS 31 de mayo de 2026 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0,11% 57 134 NS 30 de abril de 2026 N-PORT
BBSC · J.P. Morgan Exchange-Traded Fund Tr… 0,10% 81 871 NS 30 de abril de 2026 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0,07% 1 339 774 SH 8 de agosto de 2026 Diario
ISCG · iShares Trust 0,07% 73 787 SH 8 de agosto de 2026 Diario
IWM · iShares Trust 0,07% 5 925 076 SH 8 de agosto de 2026 Diario
PRFZ · Invesco Exchange-Traded Fund Trust 0,07% 206 325 SH 8 de agosto de 2026 Diario
RSSL · Global X Funds 0,06% 97 958 NS 30 de abril de 2026 N-PORT
DFAS · Dimensional ETF Trust 0,05% 806 097 NS 30 de abril de 2026 N-PORT
ITWO · ProShares Trust 0,05% 10 652 NS 31 de mayo de 2026 N-PORT
SCHA · SCHWAB STRATEGIC TRUST 0,05% 1 154 262 NS 31 de mayo de 2026 N-PORT
VBK · VANGUARD INDEX FUNDS 0,04% 1 696 014 SH 8 de agosto de 2026 Diario
ISCB · iShares Trust 0,03% 10 494 SH 8 de agosto de 2026 Diario
FHLC · FIDELITY COVINGTON TRUST 0,03% 96 151 NS 30 de abril de 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0,03% 2 837 341 SH 8 de agosto de 2026 Diario
VHT · VANGUARD WORLD FUND 0,03% 624 412 SH 8 de agosto de 2026 Diario
UWM · ProShares Trust 0,03% 8 331 NS 31 de mayo de 2026 N-PORT
URTY · ProShares Trust 0,02% 8 425 NS 31 de mayo de 2026 N-PORT
VB · VANGUARD INDEX FUNDS 0,02% 2 922 024 SH 8 de agosto de 2026 Diario
WSML · iShares Trust 0,02% 11 689 SH 8 de agosto de 2026 Diario
MSSM · MORGAN STANLEY PATHWAY FUNDS 0,01% 9 529 NS 31 de mayo de 2026 N-PORT
HDG · ProShares Trust 0,01% 212 NS 31 de mayo de 2026 N-PORT
ONEQ · Fidelity Commonwealth Trust 0,01% 80 493 NS 31 de mayo de 2026 N-PORT
DFUS · Dimensional ETF Trust 0,00% 74 317 NS 30 de abril de 2026 N-PORT
IWV · iShares Trust 0,00% 72 218 SH 8 de agosto de 2026 Diario
AVUQ · AMERICAN CENTURY ETF TRUST 0,00% 937 NS 31 de mayo de 2026 N-PORT
ITOT · iShares Trust 0,00% 336 352 SH 8 de agosto de 2026 Diario
SCHB · SCHWAB STRATEGIC TRUST 0,00% 141 645 NS 31 de mayo de 2026 N-PORT
TILT · FlexShares Trust 0,00% 6 314 NS 30 de abril de 2026 N-PORT
DFAC · Dimensional ETF Trust 0,00% 34 873 NS 30 de abril de 2026 N-PORT
DFAT · Dimensional ETF Trust 0,00% 8 956 NS 30 de abril de 2026 N-PORT
FSCC · Federated Hermes ETF Trust 0,00% 129 NS 31 de mayo de 2026 N-PORT
DFAU · Dimensional ETF Trust 0,00% 3 019 NS 30 de abril de 2026 N-PORT
VTI · VANGUARD INDEX FUNDS 0,00% 8 070 274 SH 8 de agosto de 2026 Diario